Alumis (ALMS) | Financial Analysis & Statements
Alumis Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.9M
Operating Income
-96.4M
-4,999.74%
Net Income
-92.9M
-4,817.57%
Balance Sheet Metrics
Total Assets
411.9M
Total Liabilities
110.6M
Shareholders Equity
301.3M
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
-77.0M
Free Cash Flow
-71.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Alumis Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 24.0M | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 386.0M | 265.6M | 137.7M | 101.3M |
| Selling, General & Administrative | 91.9M | 35.2M | 20.5M | 12.5M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 477.9M | 300.8M | 158.2M | 113.8M |
| Operating Income | -453.8M | -300.8M | -158.2M | -113.8M |
| Operating Margin % | -1,886.9% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 14.2M | 12.0M | 3.4M | 2.0M |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | 187.7M | -5.5M | -187.0K | -72.0K |
| Pre-tax Income | -251.9M | -294.2M | -155.0M | -111.9M |
| Income Tax | -8.6M | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -243.3M | -294.2M | -155.0M | -111.9M |
| Net Margin % | -1,011.7% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -638.2M | -292.2M | -156.8M | -113.6M |
| EPS (Basic) | - | $-10.38 | $-4.06 | $-2.91 |
| EPS (Diluted) | - | $-10.38 | $-4.06 | $-2.91 |
| Basic Shares Outstanding | - | 28341866 | 38190750 | 38410615 |
| Diluted Shares Outstanding | - | 28341866 | 38190750 | 38410615 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Alumis Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 89.7M | 169.5M | 46.0M | 25.6M |
| Short-term Investments | 218.8M | 118.7M | 3.0M | 67.3M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Other Current Assets | 1.1M | 762.0K | - | - |
| Total Current Assets | 318.2M | 306.2M | 53.4M | 102.6M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 22.8M | 18.0M | 16.4M | 3.6M |
| Goodwill | 51.0M | - | - | - |
| Intangible Assets | - | - | - | - |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 7.6M | 1.1M | 1.0M | 1.1M |
| Total Non-Current Assets | 93.7M | 34.8M | 36.3M | 5.6M |
| Total Assets | 411.9M | 341.0M | 89.6M | 108.2M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 10.1M | 9.6M | 1.1M | 1.7M |
| Short-term Debt | 4.7M | 1.6M | 1.7M | 1.3M |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Total Current Liabilities | 73.3M | 50.9M | 20.9M | 13.4M |
| Non-Current Liabilities | ||||
| Long-term Debt | 32.2M | 29.2M | 30.9M | 469.0K |
| Deferred Tax Liabilities | 2.1M | - | - | - |
| Other Non-Current Liabilities | 330.0K | 814.0K | 1.8M | 4.1M |
| Total Non-Current Liabilities | 37.3M | 30.0M | 408.0M | 290.1M |
| Total Liabilities | 110.6M | 80.9M | 428.9M | 303.4M |
| Equity | ||||
| Common Stock | 10.0K | 4.0K | 1.0K | 1.0K |
| Retained Earnings | -901.9M | -658.6M | -364.3M | -209.3M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 301.3M | 260.1M | -339.3M | -195.2M |
| Key Metrics | ||||
| Total Debt | 36.9M | 30.7M | 32.6M | 1.8M |
| Working Capital | 244.9M | 255.3M | 32.5M | 89.2M |
Balance Sheet Composition
Alumis Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -243.3M | -294.2M | -155.0M | -111.9M |
| Depreciation & Amortization | 3.5M | 3.2M | 1.3M | 250.0K |
| Stock-Based Compensation | 43.5M | 19.5M | 8.6M | 6.0M |
| Working Capital Changes | -10.5M | 6.6M | -786.0K | 474.0K |
| Operating Cash Flow | -393.0M | -264.9M | -143.9M | -104.3M |
| Investing Activities | ||||
| Capital Expenditures | -653.0K | -1.7M | -4.5M | -2.4M |
| Acquisitions | - | - | - | - |
| Investment Purchases | -209.2M | -240.1M | -11.3M | -209.1M |
| Investment Sales | 448.0M | 128.0M | 76.2M | 142.7M |
| Investing Cash Flow | 287.9M | -113.8M | 60.5M | -68.8M |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | - | - | - |
| Financing Cash Flow | 0 | 491.8M | 89.3M | 99.9M |
| Free Cash Flow | -370.2M | -256.8M | -134.5M | -110.1M |
| Net Change in Cash | -105.1M | 113.1M | 5.9M | -73.2M |
Cash Flow Trend
Alumis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.17
Forward P/E
-7.71
Price to Book
8.66
Price to Sales
131.85
PEG Ratio
-7.71
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-5,067.13%
Return on Equity
-86.68%
Return on Assets
-73.36%
Financial Health
Current Ratio
4.34
Debt to Equity
12.25
Per Share Data
EPS (TTM)
$-2.86
Book Value per Share
$2.88
Revenue per Share
$0.28
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALMS | 3.2B | 0.17 | 8.66 | -86.68% | 0.00% | 12.25 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






